Profile

Ideal

Acceptable

Target population Both NVP-exposed and non-exposed HIV+ children under 3 year old Both NVP-exposed and non-exposed HIV+ children under 3 year old
Dosing frequency Once-daily Twice-daily
Formulation Water-soluble, dispersible tablet dosage form that can be used with small amount of liquid (suitable for 2 to 36 months old) Sprinkles dosage form may work. Crushable pill that can be used in “food” may be acceptable
Pill burden 1 (scored) pill – usable across broad weight bands (WHO table) If 2 pills, must be same tablet count (or same fraction) for both
Durability High genetic barrier (PI-like). Long plasma half-life. High genetic barrier (PI-like). Long plasma half-life.
Efficacy Same as for adults Same as for adults
Safety/tolerability Well tolerated and no laboratory monitoring needed No laboratory monitoring needed
Palatability (taste) No taste or nice taste for children Palatable
Drug-drug interaction
(TB Rx)
No drug-drug interaction with TB medicines, particularly rifampicin or rifabutin Some drug-drug interaction with TB medicines, but can be used with proper dose adjustments
Stability No cold chain requirement, minimum 2 years shelf life at room temperature No cold chain requirement, minimum 2 years shelf life at room temperature
Cost < 50 USD/patient/year (consistent with adult ART) To be investigated